NFKB1 and ovarian cancer: Our results strongly suggest that the resistance of ovarian cancer cells treated with cisplatin could in part be also due to the activation of NF-κB and that the chemo-sensitization could be due to genistein-induced inactivation of NF-κB signaling, resulting in the inhibition of cell proliferation and induction of apoptosis (Figure.